Actively Recruiting
Open-Label Expanded Access Study of QRX003 Lotion Applied Topically in People 14 and Older With Netherton Syndrome
Led by Quoin Pharmaceuticals · Updated on 2026-08-31
8
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating QRX003, an investigational topical lotion, for treating Netherton syndrome, a genetic skin condition. This study aims to understand if applying QRX003 twice daily improves symptoms like diseased skin area, itch, and discomfort in adults and minors. It also seeks to assess the safety of QRX003 and how many participants may need additional rescue therapy. Participants will apply QRX003 lotion, containing 4% active drug, to all affected skin areas except the scalp twice daily for 12 weeks. The study is open-label with a single treatment group. During the treatment period, participants will visit the clinic every 4 to 6 weeks for checkups and assessments, and they will keep a dosing diary to record application times. Throughout the study, participants will undergo evaluations of their skin condition using clinical scoring and self-assessments. Researchers will measure the proportion of participants achieving at least a 1-point improvement on the Investigator Global Assessment by week 16. Safety monitoring will be conducted during clinic visits, and participants will be observed for any medical issues related to QRX003 use. The total study duration includes the 12-week treatment with follow-up evaluations.
CONDITIONS
Brief Title
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
Research Team
T
TI Clinical Research
O
Oleg G Khatsenko
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here